JP6756435B2 - Ｔｒａｉｌ誘導のためのファーマコフォア - Google Patents

Ｔｒａｉｌ誘導のためのファーマコフォア Download PDF

Info

Publication number
JP6756435B2
JP6756435B2 JP2016559887A JP2016559887A JP6756435B2 JP 6756435 B2 JP6756435 B2 JP 6756435B2 JP 2016559887 A JP2016559887 A JP 2016559887A JP 2016559887 A JP2016559887 A JP 2016559887A JP 6756435 B2 JP6756435 B2 JP 6756435B2
Authority
JP
Japan
Prior art keywords
compound
cancer
alkyl
cell
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016559887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511321A5 (enExample
JP2017511321A (ja
Inventor
キム ディー． ヤンダ
キム ディー． ヤンダ
ニコラス ティー． ジェイコブ
ニコラス ティー． ジェイコブ
ジョナサン ダブリュ． ロックナー
ジョナサン ダブリュ． ロックナー
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2017511321A publication Critical patent/JP2017511321A/ja
Publication of JP2017511321A5 publication Critical patent/JP2017511321A5/ja
Application granted granted Critical
Publication of JP6756435B2 publication Critical patent/JP6756435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016559887A 2014-03-31 2015-03-30 Ｔｒａｉｌ誘導のためのファーマコフォア Active JP6756435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
US61/972,689 2014-03-31
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019164086A Division JP6873201B2 (ja) 2014-03-31 2019-09-10 Ｔｒａｉｌ誘導のためのファーマコフォア

Publications (3)

Publication Number Publication Date
JP2017511321A JP2017511321A (ja) 2017-04-20
JP2017511321A5 JP2017511321A5 (enExample) 2018-05-10
JP6756435B2 true JP6756435B2 (ja) 2020-09-16

Family

ID=54241169

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016559887A Active JP6756435B2 (ja) 2014-03-31 2015-03-30 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2019164086A Active JP6873201B2 (ja) 2014-03-31 2019-09-10 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2021071035A Active JP7186256B2 (ja) 2014-03-31 2021-04-20 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2022188821A Active JP7688245B2 (ja) 2014-03-31 2022-11-28 Ｔｒａｉｌ誘導のためのファーマコフォア

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019164086A Active JP6873201B2 (ja) 2014-03-31 2019-09-10 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2021071035A Active JP7186256B2 (ja) 2014-03-31 2021-04-20 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2022188821A Active JP7688245B2 (ja) 2014-03-31 2022-11-28 Ｔｒａｉｌ誘導のためのファーマコフォア

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3662910B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102611067B1 (enExample)
CN (2) CN106456643B (enExample)
AU (4) AU2015241069B2 (enExample)
CA (2) CA3158795A1 (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3662910T3 (enExample)
ES (2) ES2999685T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE049013T2 (enExample)
LT (2) LT3125898T (enExample)
PL (2) PL3662910T3 (enExample)
PT (2) PT3125898T (enExample)
RS (2) RS66254B1 (enExample)
SI (2) SI3125898T1 (enExample)
SM (2) SMT202400497T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023022184A (ja) * 2014-03-31 2023-02-14 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9265765B2 (en) 2013-03-13 2016-02-23 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
CN110669047A (zh) * 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
SI3805222T1 (sl) * 2015-01-30 2025-04-30 Oncoceutics, Inc. Derivati 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(1H)-ona, njihove soli in njihova uporaba v terapiji
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
CN115844895B (zh) * 2016-01-29 2025-10-17 昂克希尔迪克斯有限公司 依米立酮化合物在制备用于治疗中枢神经系统癌症的药物中的用途
US11091483B2 (en) 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
CN113795251B (zh) 2019-02-27 2026-01-13 马德拉治疗公司 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
JP2006506401A (ja) * 2002-05-23 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
DK2303264T3 (en) * 2008-06-09 2018-05-22 Allergan Inc METHODS FOR TREATING ALPHA-ADRENERG-MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
US8691832B2 (en) * 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
MX345400B (es) * 2011-03-15 2017-01-30 Chiesi Farm Spa Derivados de isoxazolidina.
AU2012240246A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
HRP20200636T1 (hr) 2011-04-29 2020-07-10 The Penn State Research Foundation Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9265765B2 (en) * 2013-03-13 2016-02-23 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
RS66254B1 (sr) 2014-03-31 2024-12-31 Scripps Research Inst Farmakofor koji indukuje trail

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023022184A (ja) * 2014-03-31 2023-02-14 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア
JP7688245B2 (ja) 2014-03-31 2025-06-04 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア

Also Published As

Publication number Publication date
CA3158795A1 (en) 2015-10-08
CA2944452A1 (en) 2015-10-08
US10633385B2 (en) 2020-04-28
HUE049013T2 (hu) 2020-08-28
SMT202400497T1 (it) 2025-01-14
EP3662910A1 (en) 2020-06-10
CN106456643A (zh) 2017-02-22
SMT202000219T1 (it) 2020-05-08
US20240190877A1 (en) 2024-06-13
PL3125898T3 (pl) 2020-11-16
KR102473930B1 (ko) 2022-12-05
EP3125898B1 (en) 2019-12-25
EP3125898A1 (en) 2017-02-08
RS60163B1 (sr) 2020-05-29
US20190284188A1 (en) 2019-09-19
SI3125898T1 (sl) 2020-07-31
AU2022283729A1 (en) 2023-02-02
HRP20200478T1 (hr) 2020-07-24
JP2020002170A (ja) 2020-01-09
KR20220163533A (ko) 2022-12-09
FI3662910T3 (fi) 2024-10-31
ES2779979T3 (es) 2020-08-21
WO2015153468A1 (en) 2015-10-08
SI3662910T1 (sl) 2025-05-30
US11891392B2 (en) 2024-02-06
AU2020286314A1 (en) 2021-01-21
US20200283440A1 (en) 2020-09-10
DK3125898T3 (da) 2020-03-30
AU2015241069B2 (en) 2020-10-15
LT3125898T (lt) 2020-04-10
CY1123093T1 (el) 2021-10-29
CA2944452C (en) 2022-07-19
AU2015241069A1 (en) 2016-10-20
PT3662910T (pt) 2024-11-27
PL3662910T3 (pl) 2025-08-11
KR102611067B1 (ko) 2023-12-06
RS66254B1 (sr) 2024-12-31
JP7688245B2 (ja) 2025-06-04
US10239877B2 (en) 2019-03-26
PT3125898T (pt) 2020-04-01
JP6873201B2 (ja) 2021-05-19
US20170107221A1 (en) 2017-04-20
ES2999685T3 (en) 2025-02-26
EP4470617A3 (en) 2025-02-26
EP3125898A4 (en) 2017-08-16
US20220002300A1 (en) 2022-01-06
JP2023022184A (ja) 2023-02-14
EP3662910B1 (en) 2024-09-18
HUE069651T2 (hu) 2025-03-28
DK3662910T3 (en) 2024-11-04
EP4470617A2 (en) 2024-12-04
CN111499636B (zh) 2023-01-13
JP2017511321A (ja) 2017-04-20
HRP20241680T1 (hr) 2025-02-28
CN111499636A (zh) 2020-08-07
AU2024204977A1 (en) 2024-08-08
KR20160138513A (ko) 2016-12-05
JP2021119157A (ja) 2021-08-12
JP7186256B2 (ja) 2022-12-08
LT3662910T (lt) 2024-12-27
CN106456643B (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
JP6873201B2 (ja) Ｔｒａｉｌ誘導のためのファーマコフォア
JP2023518145A (ja) 化合物及びその使用
CN114364677A (zh) 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物
HK40121084A (en) Pharmacophore for trail induction
HK40035689B (en) Pharmacophore for trail induction
HK40020077A (en) Pharmacophore for trail induction
HK40020077B (en) Pharmacophore for trail induction
HK40035689A (en) Pharmacophore for trail induction
HK1223360B (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200820

R150 Certificate of patent or registration of utility model

Ref document number: 6756435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250